ByHeart is a New York-based infant nutrition company that develops whole nutrition infant formulas mimicking breast milk's protein blend, using organic, grass-fed whole milk for better digestion and nutrient absorption.[1][2][3] It serves parents seeking high-quality alternatives during formula shortages or for optimal baby health, solving the gap between outdated formulas and advancing breast milk research in a market dominated by three major players.[2][3] ByHeart has shown strong growth, raising $402.13M total (latest Series D of $95.49M two months ago), expanding to over 1,100 Walmart stores, Target, Whole Foods, Wegmans, and Publix by 2024, and building end-to-end U.S. manufacturing as one of the few fully integrated FDA-registered producers.[1][2]
ByHeart was founded in 2016 (some sources note 2017) by siblings Mia Funt and Ron Belldegrun, who identified the need for formulas closer to breast milk amid stagnant innovation despite rapid research advances.[1][2][3][4] Motivated by personal passion and industry shortcomings—where three companies control 90% of the market—they spent five years building from scratch, recruiting pediatricians, nutrition experts, and researchers.[3] Key milestones include acquiring a Reading, Pennsylvania facility in 2019 for proprietary small-batch production (becoming the fourth fully integrated U.S. formula maker), earning the first Clean Label Project Purity Award in 2021, and launching its first formula in March 2022 amid a national shortage—the first new FDA-registered U.S. formula in 15 years.[2][3] Early traction built through Cluster, an online parent community, and expansions like acquiring facilities in Oregon (2023) and Iowa.[2][3]
ByHeart rides the trend of precision nutrition and biotech applied to consumer health, leveraging systems biology, clinical trials, and data-driven R&D to disrupt a legacy infant formula industry facing shortages, contamination risks, and demands for cleaner products.[2][3][5] Timing aligned perfectly with the 2022 U.S. formula crisis, enabling rapid market entry and retail expansion amid supply chain vulnerabilities exposed by events like the FDA's 2025 botulism investigation (leading to a nationwide recall of ByHeart products).[2][5] Favorable forces include rising parental focus on microbiome/immune health, organic demand, and vertical integration to mitigate global disruptions; ByHeart influences the ecosystem by setting purity standards (e.g., Clean Label first) and proving new entrants can scale manufacturing domestically.[1][2][3]
ByHeart's momentum—$400M+ funding, national retail footprint, and clinical backing—positions it for recovery post-2025 recall, potentially through process overhauls and FDA compliance to regain trust.[1][2][5] Trends like AI-optimized nutrition, personalized formulas, and sustained clean-label demand will shape its path, with vertical integration providing a moat against shortages.[3][4] Influence may evolve toward leading U.S. innovation in baby health tech, empowering more parents with breast milk-like options if it navigates safety challenges effectively, tying back to its mission of transforming infant nutrition without compromises.[1][3]
ByHeart has raised $165.0M in total across 2 funding rounds.
ByHeart's investors include EQT Life Sciences, Kurma Partners, Polaris Partners, Pontifax Venture Capital, Vida Ventures.
ByHeart has raised $165.0M across 2 funding rounds. Most recently, it raised $95.0M Series C in May 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2024 | $95.0M Series C | EQT Life Sciences, Kurma Partners, Polaris Partners, Pontifax Venture Capital, Vida Ventures | |
| Apr 1, 2020 | $70.0M Series A | EQT Life Sciences, Kurma Partners, Polaris Partners, Pontifax Venture Capital, Vida Ventures |
